On Monday, Deutsche Börse has decided on changes in its equity indices MDAX®, SDAX® and TecDAX® that will take effect on 19 March. Symrise will be included in MDAX and will replace Schwarz Pharma. Symrise was admitted on the basis of the so-called fast-entry rule, because the company is ranked 40th or better in terms of both market capitalization and trading volume. Schwarz Pharma will move to SDAX replacing Highlight. In TecDAX BB Medtech will be included replacing the share of Evotec.
The next equity index review is scheduled for 5 June 2007.
DAX®, MDAX®, SDAX® and TecDAX® are registered trademarks of Deutsche Börse AG.
